journal article·2025-01Open access

Donor Substitution Engineering of Hemicyanine Nanoparticles to Reprogram the Tumor Microenvironment and Enhance Fn14‐Targeted BiTE for Glioblastoma Photoimmunotherapy

Gaowei Li, Shichao Jiang, Zongliang Zhang, Xiaoyin Liu, Kai Wu, Peng Liu, Mei Yang, Ting Zhou, Jiamei Xiao, Nini Xin, Xiaoyang Wu, Zhihong Chen, Jie Ding, Chengheng Wu, Dan Wei, Jing Sun, Aiping Tong, Hongsong Fan, Liangxue Zhou

Advanced Functional Materials· Volume 35· Issue 3

Abstract

Abstract Glioblastoma (GBM) is a highly malignant intracranial tumor with limited treatment options. Bispecific T‐cell engagers (BiTEs) are being explored for GBM treatment, but their success is hindered by inadequate T cell infiltration and activation due to the acidic and immunosuppressive microenvironment. Photothermal immunotherapy lyses tumors and activates immune responses, complementing BiTEs. This study innovatively employs a donor engineering strategy to develop hemicyanine dyes (Hcys) that emit from near‐infrared (NIR) I to NIR II. The Hcy with excellent properties is encapsulated in an amphiphilic micelle, forming a nano assembly with lactate oxidase (PLH1100). PLH1100 exhibits spectral absorption at 980 nm, a photothermal conversion efficiency of 58.7%, and capability for NIR‐II tumor imaging. Besides photothermal tumor ablation, PLH1100 regulates lactic acid metabolism and activates immunogenic cell death, improving the tumor microenvironment and promoting T cell infiltration and activation. Further studies demonstrate PLH1100 effectively kills human and murine GBM cells, inhibits orthotopic U87 tumor growth in BALB/c‐nu mice, and enhances the efficacy of Fn14‐targeted BiTE in orthotopic GL261 tumors in C57BL/6 mice, achieving a synergistic “1+1>2” therapeutic effect. Collectively, this work opens a new pathway for using Hcy‐based molecules combined with BiTE drugs for GBM therapy, with significant clinical potential.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery West China Hospital West China Medical School Sichuan University Chengdu Sichuan 610041 China

National Engineering Research Center for Biomaterials College of Biomedical Engineering Sichuan University Chengdu Sichuan 610064 China

State Key Laboratory of Biotherapy and Cancer Center Research Unit of Gene and Immunotherapy Chinese Academy of Medical Sciences Collaborative Innovation Center of Biotherapy West China Hospital Sichuan University Chengdu Sichuan 610041 China

Department of Neurosurgery NHC Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital) School of Medicine University of Electronic Science and Technology of China Mianyang Sichuan 621000 China

Department of Neurosurgery Fifth People’s Hospital of Ningxia Hui Autonomous Region Shizuishan Ningxia 753000 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Sichuan Province · China Postdoctoral Science Foundation

References (81)

Show source-provided references
1. 10.1093/neuonc/noad14910.1093/neuonc/noad149 ↗
2. 10.1001/jama.2023.002310.1001/jama.2023.0023 ↗
3. 10.1038/s41572-024-00516-y10.1038/s41572-024-00516-y ↗
4. 10.1038/s41573-024-00896-610.1038/s41573-024-00896-6 ↗
5. 10.1038/s41571-024-00905-y10.1038/s41571-024-00905-y ↗
6. 10.1158/1535-7163.MCT-20-050810.1158/1535-7163.MCT-20-0508 ↗
7. 10.1158/1535-7163.MCT-22-020110.1158/1535-7163.MCT-22-0201 ↗
8. 10.1007/s11060-024-04564-y10.1007/s11060-024-04564-y ↗
9. 10.1158/0008-5472.CAN-13-323310.1158/0008-5472.CAN-13-3233 ↗
10. 10.1158/1541-7786.MCR-08-000510.1158/1541-7786.MCR-08-0005 ↗
11. 10.1016/j.jhep.2020.11.01810.1016/j.jhep.2020.11.018 ↗
12. 10.1038/nrd248810.1038/nrd2488 ↗
13. 10.1080/2162402X.2021.198330610.1080/2162402X.2021.1983306 ↗
14. 10.1038/s41467-023-44308-610.1038/s41467-023-44308-6 ↗
15. 10.1126/scitranslmed.abd152410.1126/scitranslmed.abd1524 ↗
16. 10.1136/jitc-2023-00668010.1136/jitc-2023-006680 ↗
17. 10.1186/s12967-024-05301-910.1186/s12967-024-05301-9 ↗
18. 10.1186/s13045-024-01544-710.1186/s13045-024-01544-7 ↗
19. 10.1038/s41467-019-12771-910.1038/s41467-019-12771-9 ↗
20. 10.2147/IJN.S40502010.2147/IJN.S405020 ↗
21. 10.1038/s41467-023-40851-410.1038/s41467-023-40851-4 ↗
22. 10.1016/j.biomaterials.2023.12208910.1016/j.biomaterials.2023.122089 ↗
23. 10.1021/acsnano.4c0125310.1021/acsnano.4c01253 ↗
24. 10.1021/acsnano.3c0369610.1021/acsnano.3c03696 ↗
25. 10.1002/adfm.20231023710.1002/adfm.202310237 ↗
26. 10.1016/j.actbio.2023.05.03710.1016/j.actbio.2023.05.037 ↗
27. 10.1097/CJI.000000000000048510.1097/CJI.0000000000000485 ↗
28. 10.1002/adma.20231087510.1002/adma.202310875 ↗
29. 10.1021/acsnano.2c0749110.1021/acsnano.2c07491 ↗
30. 10.1007/s42114-024-00886-710.1007/s42114-024-00886-7 ↗
31. 10.1016/j.it.2022.10.00510.1016/j.it.2022.10.005 ↗
32. 10.1016/j.ebiom.2021.10362710.1016/j.ebiom.2021.103627 ↗
33. 10.1126/sciimmunol.aan463110.1126/sciimmunol.aan4631 ↗
34. 10.1002/anie.20210590510.1002/anie.202105905 ↗
35. 10.1002/anie.20210787710.1002/anie.202107877 ↗
36. 10.1002/smll.20220485110.1002/smll.202204851 ↗
37. 10.1002/anie.20221140910.1002/anie.202211409 ↗
38. 10.1126/scitranslmed.add271210.1126/scitranslmed.add2712 ↗
39. 10.1038/s41467-022-31799-y10.1038/s41467-022-31799-y ↗
40. 10.1016/j.apsb.2022.10.02110.1016/j.apsb.2022.10.021 ↗
41. 10.1002/anie.20190692910.1002/anie.201906929 ↗
42. 10.1002/adfm.20230169210.1002/adfm.202301692 ↗
43. An N. · Adv. Mater. · 2020 · 32 · 1
44. 10.1002/adfm.20231677310.1002/adfm.202316773 ↗
45. 10.1002/adfm.20240553910.1002/adfm.202405539 ↗
46. Liu J. · Adv. Mater. · 2023 · 35
47. 10.1002/adfm.20231088110.1002/adfm.202310881 ↗
48. 10.1016/j.biomaterials.2012.01.02510.1016/j.biomaterials.2012.01.025 ↗
49. 10.1016/j.biomaterials.2011.05.06410.1016/j.biomaterials.2011.05.064 ↗
50. 10.1038/s41417-024-00766-810.1038/s41417-024-00766-8 ↗
51. 10.1093/neuonc/noy06310.1093/neuonc/noy063 ↗
52. 10.1038/onc.2015.31010.1038/onc.2015.310 ↗
53. 10.1016/j.ccell.2017.02.00210.1016/j.ccell.2017.02.002 ↗
54. 10.1158/1078-0432.CCR-18-275210.1158/1078-0432.CCR-18-2752 ↗
55. 10.1073/pnas.171990511510.1073/pnas.1719905115 ↗
56. 10.1158/1078-0432.CCR-18-392710.1158/1078-0432.CCR-18-3927 ↗
57. 10.1073/pnas.121981711010.1073/pnas.1219817110 ↗
58. 10.1002/adma.20220809710.1002/adma.202208097 ↗
59. 10.1002/adma.20210608210.1002/adma.202106082 ↗
60. 10.1038/s41467-024-44737-x10.1038/s41467-024-44737-x ↗
61. 10.1002/adma.20230877410.1002/adma.202308774 ↗
62. 10.1002/smll.20230949510.1002/smll.202309495 ↗
63. 10.1002/smll.20240091910.1002/smll.202400919 ↗
64. 10.1126/scitranslmed.aaw784310.1126/scitranslmed.aaw7843 ↗
65. 10.1158/0008-5472.CAN-20-178510.1158/0008-5472.CAN-20-1785 ↗
66. 10.1172/jci.insight.17985410.1172/jci.insight.179854 ↗
67. 10.1096/fj.202101736R10.1096/fj.202101736R ↗
68. 10.1016/j.ccell.2024.04.01110.1016/j.ccell.2024.04.011 ↗
69. 10.1038/s41573-022-00520-510.1038/s41573-022-00520-5 ↗
70. 10.1038/s41571-024-00870-610.1038/s41571-024-00870-6 ↗
71. 10.1080/2162402X.2024.233896510.1080/2162402X.2024.2338965 ↗
72. 10.1016/j.jconrel.2024.03.04310.1016/j.jconrel.2024.03.043 ↗
73. 10.1038/s42255-022-00676-910.1038/s42255-022-00676-9 ↗
74. 10.1158/2326-6066.CIR-20-011110.1158/2326-6066.CIR-20-0111 ↗
75. 10.1038/s41586-020-03045-210.1038/s41586-020-03045-2 ↗
76. 10.1016/j.canlet.2024.21676010.1016/j.canlet.2024.216760 ↗
77. 10.1080/2162402X.2022.212750810.1080/2162402X.2022.2127508 ↗
78. 10.1038/s41467-023-39683-z10.1038/s41467-023-39683-z ↗
79. 10.1007/s00262-024-03757-810.1007/s00262-024-03757-8 ↗
80. 10.1002/adfm.20231136510.1002/adfm.202311365 ↗
81. 10.1002/adma.20221017910.1002/adma.202210179 ↗